Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Intramuscular botulinum toxin in complex regional pain syndrome: case series and literature review Kharkar S; Ambady P; Venkatesh Y; Schwartzman RJPain Physician 2011[Sep]; 14 (5): 419-24BACKGROUND: Pain associated with Complex Regional Pain Syndrome (CRPS) is frequently excruciating and intractable. The use of botulinum toxin for relief of CRPS-associated pain has not been well described. OBJECTIVES: To assess whether intramuscular botulinum toxin injections cause relief of pain caused by CRPS, and to assess the risks of this treatment. STUDY DESIGN: Retrospective chart review. SETTING: Outpatient clinic. METHODS: 37 patients with spasm/dystonia in the neck and/or upper limb girdle muscles. INTERVENTION: EMG-guided injection of Botulinum Toxin - A (BtxA), 10-20 units per muscle. Total dose used was 100 units in each patient. Local pain score was measured on an 11-point Likert scale, 4 weeks after BtxA injections. RESULTS: Mean pain score decreased by 43% (8.2 +/- 0.8 to 4.5 +/- 1.1, P < 0.001). 97% patients had significant pain relief. One patient had transient neck drop after the injections. LIMITATIONS: This is a retrospective study, it lacks a control group and hence the placebo effect cannot be eliminated. This study does not provide information on the efficacy of this treatment after 4 weeks. CONCLUSIONS: Intramuscular injection of botulinum toxin in the upper limb girdle muscles was beneficial for short term relief of pain caused by CRPS. The incidence of complications was low (2.7%).|Botulinum Toxins, Type A/*therapeutic use[MESH]|Complex Regional Pain Syndromes/classification/*drug therapy[MESH]|Electromyography[MESH]|Female[MESH]|Humans[MESH]|Injections, Intramuscular[MESH]|Likelihood Functions[MESH]|Male[MESH]|Neuromuscular Agents/*therapeutic use[MESH]|Pain Measurement[MESH]|Peptide Fragments/*therapeutic use[MESH]|Retrospective Studies[MESH] |